{'52WeekChange': 0.5434085,
 'SandP52WeekChange': 0.0644362,
 'address1': '500 Unicorn Park',
 'address2': '3rd Floor',
 'algorithm': None,
 'annualHoldingsTurnover': None,
 'annualReportExpenseRatio': None,
 'ask': 24,
 'askSize': 2200,
 'averageDailyVolume10Day': 148225,
 'averageVolume': 220552,
 'averageVolume10days': 148225,
 'beta': 3.368087,
 'beta3Year': None,
 'bid': 10,
 'bidSize': 1100,
 'bookValue': 5.01,
 'category': None,
 'circulatingSupply': None,
 'city': 'Woburn',
 'companyOfficers': [],
 'country': 'United States',
 'currency': 'USD',
 'dateShortInterest': 1593475200,
 'dayHigh': 19.7293,
 'dayLow': 18.735,
 'dividendRate': None,
 'dividendYield': None,
 'earningsQuarterlyGrowth': None,
 'enterpriseToEbitda': -11.295,
 'enterpriseToRevenue': None,
 'enterpriseValue': 579489280,
 'exDividendDate': None,
 'exchange': 'NMS',
 'exchangeTimezoneName': 'America/New_York',
 'exchangeTimezoneShortName': 'EDT',
 'expireDate': None,
 'fiftyDayAverage': 22.082857,
 'fiftyTwoWeekHigh': 26.22,
 'fiftyTwoWeekLow': 8.58,
 'fiveYearAverageReturn': None,
 'fiveYearAvgDividendYield': None,
 'floatShares': 14691582,
 'forwardEps': -2.16,
 'forwardPE': -8.888889,
 'fromCurrency': None,
 'fullTimeEmployees': 122,
 'fundFamily': None,
 'fundInceptionDate': None,
 'gmtOffSetMilliseconds': '-14400000',
 'heldPercentInsiders': 0.15511,
 'heldPercentInstitutions': 0.88941,
 'industry': 'Biotechnology',
 'isEsgPopulated': False,
 'lastCapGain': None,
 'lastDividendValue': None,
 'lastFiscalYearEnd': 1585612800,
 'lastMarket': None,
 'lastSplitDate': None,
 'lastSplitFactor': None,
 'legalType': None,
 'logo_url': 'https://logo.clearbit.com/replimune.com',
 'longBusinessSummary': 'Replimune Group, Inc., a biotechnology company, '
                        'develops oncolytic immune-gene therapies to treat '
                        'cancer. It uses its proprietary Immulytic platform to '
                        'design and develop product candidates that are '
                        'intended to activate the immune system against '
                        "cancer. The company's lead product candidate is RP1, "
                        'a selectively replicating version of herpes simplex '
                        'virus 1, which is in Phase I/II clinical trials for a '
                        'range of solid tumors; and that is in Phase II '
                        'clinical trials for patients with cutaneous squamous '
                        'cell carcinoma. It is also developing RP2, which is '
                        'in Phase I clinical trials for an anti-CTLA-4 '
                        'antibody-like protein in order to block the '
                        'inhibition of the immune response otherwise caused by '
                        'CTLA-4; and RP3 to express immune-activating proteins '
                        'that stimulate T cells. Replimune Group, Inc. was '
                        'founded in 2015 and is headquartered in Woburn, '
                        'Massachusetts.',
 'longName': 'Replimune Group, Inc.',
 'market': 'us_market',
 'marketCap': 773038080,
 'maxAge': 1,
 'maxSupply': None,
 'messageBoardId': 'finmb_571664452',
 'morningStarOverallRating': None,
 'morningStarRiskRating': None,
 'mostRecentQuarter': 1585612800,
 'navPrice': None,
 'netIncomeToCommon': -52625000,
 'nextFiscalYearEnd': 1648684800,
 'open': 19.67,
 'openInterest': None,
 'payoutRatio': 0,
 'pegRatio': None,
 'phone': '781 222 9600',
 'previousClose': 19.79,
 'priceHint': 2,
 'priceToBook': 3.8323352,
 'priceToSalesTrailing12Months': None,
 'profitMargins': 0,
 'quoteType': 'EQUITY',
 'regularMarketDayHigh': 19.7293,
 'regularMarketDayLow': 18.735,
 'regularMarketOpen': 19.67,
 'regularMarketPreviousClose': 19.79,
 'regularMarketPrice': 19.67,
 'regularMarketVolume': 199733,
 'revenueQuarterlyGrowth': None,
 'sector': 'Healthcare',
 'sharesOutstanding': 40262400,
 'sharesPercentSharesOut': 0.0138,
 'sharesShort': 556847,
 'sharesShortPreviousMonthDate': 1590710400,
 'sharesShortPriorMonth': 419753,
 'shortName': 'Replimune Group, Inc.',
 'shortPercentOfFloat': 0.0269,
 'shortRatio': 1.6,
 'startDate': None,
 'state': 'MA',
 'strikePrice': None,
 'symbol': 'REPL',
 'threeYearAverageReturn': None,
 'toCurrency': None,
 'totalAssets': None,
 'tradeable': False,
 'trailingAnnualDividendRate': None,
 'trailingAnnualDividendYield': None,
 'trailingEps': -1.536,
 'twoHundredDayAverage': 17.020756,
 'volume': 199733,
 'volume24Hr': None,
 'volumeAllCurrencies': None,
 'website': 'http://replimune.com',
 'yield': None,
 'ytdReturn': None,
 'zip': '01801'}